Conference Program

Best of ASCO® Bangkok 2019

2-3 August 2019 at AVANI Riverside Bangkok Hotel BANGKOK, THAILAND

Download : PDF version (Save target as, Save link as)
       Day 1_Program BOA 2019
       Day 2_Program BOA 2019

August 2-3, 2019
AVANI Riverside
Bangkok Hotel


Online Registrationto attend BOA Bangkok 2019

Tentative Program: Best of ASCO Bangkok 2019 (Day 1: 2nd August 2019)

Time Abstract ID Title Presenter Moderator
7:30-8:30 Trainee session
(Thai language)
Real-world tumor/ plasma genetic testing: tough choices, how do you pick? Assist.Prof.THANYANAN REUNGWETWATTANA,
8.30-9.30 Trainee session
(Thai language)
Care of Oligometastatic Disease: Enhancing Survival or Increasing Toxicity? NAPAPAT AMORNWICHET, M.D.,
9:30-9:40 Opening and welcome message Assoc.Prof.EKAPHOP SIRACHAINAN  
    Scientific Agenda Assoc.Prof.SUTHINEE ITHIMAKIN  
9:45-10:30   Symposium Bristol-Myers Squibb  : Data of immune checkpoint inhibitors in second-line NSCLC treatment: enhancement in long term survival  Prof.Neal Edward Ready,
Duke cancer institute USA
10:30-10:50   Exhibition    
    CNS tumor and sarcoma session    
10:50-11:02 LBA3 ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS). TOUCH ATIVITAVAS, M.D. KASAN SEETALAROM, M.D.
11:02-11:14 11000 Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Final results of a randomized clinical trial from the Italian Sarcoma Group, the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG). CHAWALIT CHAYANGSU, M.D.  
11:14-11.26 2000 Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion Assoc.Prof.SITH SATHORNSUMETEE  
11:26-11:40   Q&A  panelists   
11:45-12:30   Symposium Pfizer: Raising the Bar in Breast Cancer Care: CDK 4/6 Inhibitor Prof. Hamdy Abdel Azim
Faculty of Medicine, Cairo University, Egypt
 Assoc Prof. Chaiyut Charoentum
12:30-12:50   Exhibition    
  Early Breast cancer session  
12:50-13:00 503 Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx. Assist.Prof.THITIYA  DEJTHEVAPORN Assist.Prof.AUMKHAE  SOOKPRASERT
13:00-13:10 504 Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM). PIYAWAN TIENCHAIANANDA, M.D.  
13:10-13:20 500 Neoadjuvant trastuzumab, pertuzumab (P) and chemotherapy versus trastuzumab emtansine (TDM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer: Final outcome results from the phase III KRISTINE study Assist. Prof.CHARUWAN AKEWANLOP  
13:20-13:40 Discussion/ Q&A  Discussant:  Prof. Hamdy Abdel Azim, Q&A: panelists  
13:40-14:25   Symposium Eisai: Systemic treatment landscape for advanced hepatocellular carcinoma Dr.Zhong-Zhe Lin,
National Taiwan University Hospital, Taipei, Taiwan
14:25-14:45   Exhibition     
    Non-colorectal GI cancer    Assoc.Prof.EKAPHOP SIRACHAINAN
14:45-14:55 4000 APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. KULATIDA MANEENIL, M.D.  
14:55-15:05 LBA4 Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial. Assist.Prof. SUEBPONG TANASANVIMON  
15:05-15:15 4003 ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. TEERAPAT UNGTRAKUL, M.D.   
15:15-15:35   Discussion/ Q&A  Discussant: TOUCH ATIVITAVAS, M.D.,
Q&A: panelists
    Colorectal cancer session     
15:40-15:50 3501 Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC). Assist.Prof. SUEBPONG TANASANVIMON Prof.VORACHAI RATANATHARATHORN
15:50-16:00 3508 Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC. Assist.Prof.NUTTAPONG NGAMPHAIBOON  
16:00-16:10 3504 FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. Assist.Prof. KRITTIYA KORPHAISARN  
16:10-16:30   Discussion/ Q&A  Discussant: Prof. John Allen Bridgewater, Q&A: panelists   
16:30-17:15   Symposium Amgen: Making a difference in 1st line mCRC treatment Prof. John Allen Bridgewater
UCL Cancer Institute, London, UK

End of day 1

Tentative Program: Best of ASCO Bangkok 2019 (Day 2: 3rd August 2019)

Time Abstract ID Title Presenter Moderator
8:00-8:45   Symposium Mylan : Management of HER2+ Breast cancer - What's changing and where are we with Biosimilar Trastuzumab? Prof.Hope Rugo
Breast Oncology and Clinical Trials Education UCSF Helen Diller Family Comprehensive Cancer Center, CA, USA
    Metastatic breast cancer session     
8:45-8:55 1003 IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). NAPA PARINYANITIKUL, M.D. Assoc. Prof.VICHIEN  SRIMUNINNIMIT
8:55-9:05 LBA1008 Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results. Assist.Prof.AUMKHAE  SOOKPRASERT  
9:05-9:15 1002 Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. Assoc.Prof.SUTHINEE ITHIMAKIN  
9:15-9:35   Discussion/ Q&A  Discussant:Prof.Hope Rugo, Q&A: panelists  
9:35-10:20   Symposium Roche: Immunotherapy in mTNBC: Today's imperative to fullfill the current unmet needs Tira Jing Ying Tan, M.D.
National Cancer Centre Singapore

10.20-10.40   Exhibition     
    Head and neck cancer session    
10:40-10:52 6000 Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Assist.Prof.NUTTAPONG NGAMPHAIBOON Assist. Prof.CHARUWAN AKEWANLOP
10:52-11:04 6002 TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Assist Prof. CHANYOOT  BANDIDWATTANAWONG  
11:04-11:16 6003 Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial. Assoc.Prof.PATRAPIM SUNPAWERAVONG  
11:16-11:35   Q&A  Panelists  
11:40-12:25   Symposium MSD: Emerging Therapeutic Landscape in Mutation (-) Advanced Non-small cell lung Cancer (NSCLC) :  Surein Arulananda, M.D.
Epworth Freemasons Hospital
Melbourne, Australia
 Assoc Prof. Chaiyut Charoentum
12:25-12:45   The New Immunotherapy Paradigm     
  supportive and survivor care    
12:45-12:57 11501 A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration-resistant prostate cancer. Assoc.Prof.SUTHINEE ITHIMAKIN Assoc.Prof.BUSYAMAS CHEWASKULYONG
12:57-13:09 11503 A randomized, double-blind, placebo-controlled phase III trial evaluating olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: J-FORCE Study. YOTSAWAJ RUNGLODVATANA, M.D.
13:09-13:21 11505 Randomized controlled trial of patient navigation intervention to increase early access to supportive care for patients with metastatic cancer in a resource-limited setting NAIYARAT PRASONGSOOK, M.D.  
13:21-13:35 Q&A  Panelists  
    Lung cancer session    
13:35-13:45 9000 RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC). Assist.Prof.THANYANAN REUNGWETWATTANA Clin.Prof. SUDSAWAT LAOHAVINIJ
13:45-13:55 9001 Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C). PIYADA SITTHIDEATPHAIBOON, M.D.  
13:55-14:05 8501 Randomized phase III study of pemetrexed/cisplatin (Pem/Cis) versus vinorelbine /cisplatin (Vnr/Cis) for completely resected stage II-IIIA non-squamous non-small-cell lung cancer (Ns-NSCLC): The JIPANG study. KULATIDA MANEENIL, M.D.  
14:05-14:25   Discussion/ Q&A  Discussant: Assoc.Prof.VIROTE SRIURANPONG , Q&A: Panelists  
14:30-15:15   Symposium AstraZeneca: Advances in management of unresectable stage III NSCLC: Where are we now? Prof.Kuo Chih-HSI
Linkou Chang Gung Memorial Hospital, Taiwan
15:15-15:35   Exhibition    
  Genitourinary cancer session  
15:35-15:47 LBA2 Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial. PHICHAI CHANSRIWONG, M.D. Assoc.Prof.CHAIYUT CHAROENTUM
15:47-15:59 5006 First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). JARIN CHINDAPRASIRT, M.D.  
15:59-16:11 4502 Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810). NATTAYA  POOVORAWAN, M.D.  
16:11-16:23 4500 Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. PONGWUT DANCHIVIJITR, M.D.  
16:23-16:40 Q&A  Panelists  
16:40-16:45   Closing Remark Assoc.Prof.EKAPHOP SIRACHAINAN